Literature DB >> 29461273

Relationship of surgeon/hospital volume with outcomes in uro-oncology surgery.

Pietro Grande1,2, Riccardo Campi1,3, Morgan Rouprêt1.   

Abstract

PURPOSE OF REVIEW: Hospital and surgical volumes, as well as complications, are considered to influence intra and postoperative results in most surgical operations. This trend is also seen in uro-oncologic surgery. The objective of this review is to critically analyze the most recent literature to give a comprehensive overview on whether surgical and hospital volumes have an impact, and whether regionalization of the procedure should be advised. RECENT
FINDINGS: Uro-oncologic surgery has recently become more regionalized, and data coming from different population-based analyses appear to support this trend. Recent data suggest that the most beneficial procedures could be radical cystectomy, radical prostatectomy, and partial nephrectomy. For radical cystectomy, even considering different cut-off values, saw better results for postoperative complications, mortality and long-term oncological and functional outcomes in patients treated in high-volume institutions. Centralization of radical prostatectomy seems to affect short-term outcomes and costs related to prostate cancer treatment, with high-volume institutions providing more affordable treatments reducing cancer recurrence and progression. Partial nephrectomy is more frequently performed in cT1-b cancer in high-volume than low-volume institutions. Additionally, in this setting it has a higher success rate and lower complications, shorter operative time, and fewer prolonged hospital stays.
SUMMARY: Regionalization of the procedure in high-volume centers seems to have impact on postoperative morbidity and mortality for the most frequent major uro-oncological procedures: radical prostatectomy, radical cystectomy, and partial nephrectomy; but there are insufficient data available on other procedures.

Entities:  

Mesh:

Year:  2018        PMID: 29461273     DOI: 10.1097/MOU.0000000000000490

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  10 in total

1.  Factors Associated With Receipt of Partial Nephrectomy or Minimally Invasive Surgery for Patients With Clinical T1a and T1b Renal Masses: Implications for Regionalization of Care.

Authors:  Joshua Sterling; Zorimar Rivera-Núñez; Hiren V Patel; Nicholas J Farber; Sinae Kim; Kushan D Radadia; Parth K Modi; Sharad Goyal; Rahul Parikh; Robert E Weiss; Isaac Y Kim; Sammy E Elsamra; Thomas L Jang; Eric A Singer
Journal:  Clin Genitourin Cancer       Date:  2020-03-20       Impact factor: 2.872

2.  Robot-Assisted, Laparoscopic, and Open Radical Cystectomy: Pre-Operative Data of 1400 Patients From The Italian Radical Cystectomy Registry.

Authors:  Gian Maria Busetto; Daniele D'Agostino; Michele Colicchia; Katie Palmer; Walter Artibani; Alessandro Antonelli; Lorenzo Bianchi; Aldo Bocciardi; Eugenio Brunocilla; Marco Carini; Giuseppe Carrieri; Luigi Cormio; Ugo Giovanni Falagario; Ettore De Berardinis; Alessandro Sciarra; Costantino Leonardo; Francesco Del Giudice; Martina Maggi; Ottavio de Cobelli; Matteo Ferro; Gennaro Musi; Amelio Ercolino; Fabrizio Di Maida; Andrea Gallina; Carlo Introini; Ettore Mearini; Giovanni Cochetti; Andrea Minervini; Francesco Montorsi; Riccardo Schiavina; Sergio Serni; Claudio Simeone; Paolo Parma; Armando Serao; Mario Salvatore Mangano; Giorgio Pomara; Pasquale Ditonno; Alchiede Simonato; Daniele Romagnoli; Alessandro Crestani; Angelo Porreca
Journal:  Front Oncol       Date:  2022-05-05       Impact factor: 5.738

Review 3.  [Limits of surgery in uro-oncology].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2018-09       Impact factor: 0.639

4.  Open radical cystectomy: lessons from the British Association of Urological Surgeons (BAUS) registry.

Authors:  Marta Rossanese; Enrica Subba; Gianluca Giannarini; Antonino Inferrera; Vincenzo Ficarra
Journal:  Transl Androl Urol       Date:  2018-08

5.  The Intersection of Regional Anesthesia and Cancer Progression: A Theoretical Framework.

Authors:  Aaron R Muncey; Sephalie Y Patel; Christopher J Whelan; Robert S Ackerman; Robert A Gatenby
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

6.  A Retrospective Analysis of Patients Undergoing Telemedicine Evaluation in the PreAnesthesia Testing Clinic at H. Lee Moffitt Cancer Center.

Authors:  Nasrin N Aldawoodi; Aaron R Muncey; Andrew A Serdiuk; Melissa D Miller; Mark M Hanna; Jose M Laborde; Rosemarie E Garcia Getting
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

7.  The comprehensive complication index (CCI): proposal of a new reporting standard for complications in major urological surgery.

Authors:  K F Kowalewski; D Müller; J Mühlbauer; J D Hendrie; T S Worst; F Wessels; M T Walach; J von Hardenberg; P Nuhn; P Honeck; M S Michel; M C Kriegmair
Journal:  World J Urol       Date:  2020-08-19       Impact factor: 4.226

8.  Laparoscopic conversion to open surgery in radical nephrectomy and tumor thrombectomy: causal analysis, clinical characteristics, and treatment strategies.

Authors:  Zhuo Liu; Shiying Tang; Xiaojun Tian; Xun Zhao; Peng Hong; Qiming Zhang; Liwei Li; Li Zhang; Shudong Zhang; Guoliang Wang; Hongxian Zhang; Cheng Liu; Guodong Zhu; Lulin Ma
Journal:  BMC Surg       Date:  2020-08-13       Impact factor: 2.102

9.  Propofol-based total intravenous anesthesia is associated with better survival than desflurane anesthesia in robot-assisted radical prostatectomy.

Authors:  Hou-Chuan Lai; Meei-Shyuan Lee; Kuen-Tze Lin; Yi-Hsuan Huang; Jen-Yin Chen; Yao-Tsung Lin; Kuo-Chuan Hung; Zhi-Fu Wu
Journal:  PLoS One       Date:  2020-03-17       Impact factor: 3.240

10.  Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial.

Authors:  Andrea Minervini; Andrea Mari; Fabrizio Di Maida; Riccardo Campi; Marco Carini; Alberto Lapini
Journal:  Transl Cancer Res       Date:  2019-03       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.